DE932679T1 - Verfahren und zusammensetzungen zur verabreichung und expression von interferon-alpha nukleinsäuren - Google Patents

Verfahren und zusammensetzungen zur verabreichung und expression von interferon-alpha nukleinsäuren

Info

Publication number
DE932679T1
DE932679T1 DE0932679T DE97910794T DE932679T1 DE 932679 T1 DE932679 T1 DE 932679T1 DE 0932679 T DE0932679 T DE 0932679T DE 97910794 T DE97910794 T DE 97910794T DE 932679 T1 DE932679 T1 DE 932679T1
Authority
DE
Germany
Prior art keywords
interferon
promoter
polypeptide
vector
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0932679T
Other languages
English (en)
Inventor
Tattanahalli Nagabhushan
Deba Saha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canji Inc
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of DE932679T1 publication Critical patent/DE932679T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Claims (13)

:::· .··.···, .-..-PE./EP O 332 67911 Patentansprüche
1. Zusammensetzung, die einen Vektor umfaßt, wobei der Vektor einen Nukleinsäureabschnitt aufweist, der für die Expression eines Interferon &agr; Polypeptids kodiert, dadurch gekennzeichnet, daß der Nukleinsäureabschnitt operativ mit einem Gewebe-spezifischen Promotor verbunden ist.
2. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß der Vektor ein Vektor viralen Ursprungs ist.
3. . Zusammensetzung nach Anspruch 2, dadurch gekennzeichnet,
daß der Vektor viralen Ursprungs ein Adenovirus ist.
4. Zusammensetzung nach Anspruch 3, dadurch gekennzeichnet, daß der Promotor ein Leber-spezifischer Promotor ist.
5. Zusammensetzung nach Anspruch 4, dadurch gekennzeichnet, daß der Promotor ein Prostata-spezifischer Promotor ist.
6. Zusammensetzung nach Anspruch 4 oder 5, dadurch gekennzeichnet, daß die Zusammensetzung ferner eine Interferon &agr; Sekretionssequenz aufweist, welche mit der für das Interferon &agr; Polypeptid kodierenden Nukleinsäure operativ verbunden ist.
7. Pharmazeutische Zusammensetzung, dadurch gekennzeichnet, daß diese eine Zusammensetzung nach einem der Ansprüche 1 bis 6 umfaßt.
8. Verfahren zur Bereitstellung eines Interferon &agr;, Polypeptids für ein Gewebe, bei dem man in das Gewebe einen Vektor einbringt, der einen Nukleinsäureabschnitt aufweist, welcher für ein Interferon &agr; Polypeptids kodiert, dadurch gekennzeichnet, daß der Nukleinsäureabschnitt operativ mit einem Promotor verbunden ist, der für das ausgewählte Gewebe spezifisch ist, wodurch das Interferon &agr; Polypeptid in dem ausgewählten Gewebe exprimiert wird.
9. Verfahren nach Anspruch 8, dadurch gekennzeichnet, daß das Interferon &agr; Polypeptid Interferon a2b ist.
10. Verfahren nach Anspruch 9, dadurch gekennzeichnet, daß der Vektor viralen Ursprungs ein Adenovirus ist.
11. Verfahren nach Anspruch 10, dadurch gekennzeichnet, daß der Promotor ein Leber-spezifischer Promotor ist.
12. Verfahren nach Anspruch 10, dadurch gekennzeichnet, daß der Promotor ein Prostata-spezifischer Promotor ist.
13. Verfahren nach Anspruch 11 oder 12, dadurch gekennzeichnet, daß der für ein Interferon &agr; Polypeptid kodierende Nukleinsäureabschnitt operativ mit einer Nukleinsäure verbunden ist, welche für eine Interferon &agr; Sekretionssequenz kodiert.
DE0932679T 1996-10-18 1997-10-16 Verfahren und zusammensetzungen zur verabreichung und expression von interferon-alpha nukleinsäuren Pending DE932679T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73381596A 1996-10-18 1996-10-18
PCT/US1997/017928 WO1998017801A1 (en) 1996-10-18 1997-10-16 METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-α NUCLEIC ACIDS

Publications (1)

Publication Number Publication Date
DE932679T1 true DE932679T1 (de) 2000-03-09

Family

ID=24949214

Family Applications (1)

Application Number Title Priority Date Filing Date
DE0932679T Pending DE932679T1 (de) 1996-10-18 1997-10-16 Verfahren und zusammensetzungen zur verabreichung und expression von interferon-alpha nukleinsäuren

Country Status (20)

Country Link
EP (2) EP1591528A3 (de)
JP (2) JP2001502540A (de)
KR (1) KR20000049243A (de)
AR (1) AR013618A1 (de)
AU (1) AU4808097A (de)
BR (1) BR9712362A (de)
CA (1) CA2269100A1 (de)
CZ (1) CZ131699A3 (de)
DE (1) DE932679T1 (de)
ES (1) ES2136583T1 (de)
HU (1) HUP9904219A2 (de)
ID (1) ID24500A (de)
IL (1) IL129387A0 (de)
NO (1) NO991839L (de)
NZ (1) NZ335134A (de)
PL (1) PL332856A1 (de)
SK (1) SK50699A3 (de)
TR (1) TR199901190T2 (de)
WO (1) WO1998017801A1 (de)
ZA (1) ZA979295B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912925D0 (en) * 1999-06-03 1999-08-04 Angeletti P Ist Richerche Bio Adenoviral vectors encoding interferon and their use in gene therapy
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
JP4563171B2 (ja) 2002-05-24 2010-10-13 シェーリング コーポレイション 中和ヒト抗ｉｇｆｒ抗体
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
CN1893981B (zh) 2003-12-10 2011-03-23 坎基股份有限公司 用于治疗干扰素耐药性肿瘤的方法和组合物
JP2008521907A (ja) 2004-12-03 2008-06-26 シェーリング コーポレイション 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
KR101449587B1 (ko) 2006-09-14 2014-10-10 메드제닉스 메디칼 이스라엘 리미티드 장기 지속형 약물 제형
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
EP2114459B1 (de) 2007-02-23 2013-09-25 Her Majesty The Queen, In Right Of Canada, As Represented by the Minister of National Defence Rekombinante virale vektoren für vorbeugung und schutz gegen alphavirus-infektion
CA2764759A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc. Administration of interferon for prophylaxis against or treatment of pathogenic infection
CN103260649A (zh) 2010-06-15 2013-08-21 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
WO2018178215A1 (en) 2017-03-31 2018-10-04 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (nmsc)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238778C2 (de) * 1992-11-12 1995-11-02 Max Delbrueck Centrum Vektor zur Expression von therapeutisch relevanten Genen
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
ATE314482T1 (de) * 1993-10-25 2006-01-15 Canji Inc Rekombinante adenoviren-vektor und verfahren zur verwendung
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
DE4407859C1 (de) * 1994-03-04 1995-03-02 Max Planck Gesellschaft Vektor für die leberspezifische Gentherapie
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
EP1591528A3 (de) 2005-11-16
ZA979295B (en) 1998-04-20
TR199901190T2 (xx) 1999-07-21
JP2001502540A (ja) 2001-02-27
JP2008301832A (ja) 2008-12-18
AR013618A1 (es) 2001-01-10
CZ131699A3 (cs) 1999-07-14
ID24500A (id) 2000-07-20
HUP9904219A2 (hu) 2000-12-28
NZ335134A (en) 2001-05-25
WO1998017801A1 (en) 1998-04-30
SK50699A3 (en) 2000-05-16
NO991839D0 (no) 1999-04-16
EP1591528A2 (de) 2005-11-02
EP0932679A1 (de) 1999-08-04
PL332856A1 (en) 1999-10-25
IL129387A0 (en) 2000-02-17
KR20000049243A (ko) 2000-07-25
NO991839L (no) 1999-06-15
BR9712362A (pt) 1999-08-31
AU4808097A (en) 1998-05-15
ES2136583T1 (es) 1999-12-01
CA2269100A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
DE932679T1 (de) Verfahren und zusammensetzungen zur verabreichung und expression von interferon-alpha nukleinsäuren
DE278776T1 (de) Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein.
JO1365B1 (en) Laoxy repo nucleic polypeptide acid has a physiological activity on humans and includes a basic sequence for the coded arrangement of the said polypeptide and a method for producing this for polypeptide and the pharmacological composition included.
ATE79763T1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
DE159714T1 (de) Herstellung von gamma-interferon.
DE851925T1 (de) Varianten des menschlichen wachstumshormons
MY110734A (en) Improvements in or relating to dioic acids.
CA2262409A1 (en) Modified tie-2-receptor ligands
DE3712985A1 (de) Bifunktionelle proteine
EP0349342A3 (de) Polypeptide mit zellenverstreuender Aktivität
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
EP1439231A3 (de) Aminoterminalen verkürzten c-c Chemokine und als Chemokine Antagonist
DE146944T1 (de) Menschliches gamma-interferonpolypeptidderivat.
HUT64592A (en) Method for producing polypeptides with anti-thrombinic effect
DE4036856C1 (de)
DE69402861T2 (de) Verwendung eines peptids mit ein lysine und ein endständigen alanine für ein entfärbungszusammensetzung sowie ihre verwendung
IL98273A (en) Dna sequences, proteins having esterase activity coded by them and use of such proteins, pharmaceutical compositions and infant food formulations containing the proteins and processes for preparing them
WO1988006625A3 (en) Arginine-depleted human tumor necrosis factor
DE321270T1 (de) Verfahren zur Herstellung von HhaI-Restriktionsendonuklease und -methylase.
DE60028559T2 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
EP0315118A3 (de) Endothelin kodierendes DNA und dessen Verwendung
EP0324447A3 (de) Mittel und Verfahren zur Herstellung eines rekombinanten, menschlichen Interleukin-1 alpha-Polypeptides
IL85776A (en) Pharmaceutical compositions comprising certain selenium containing algae and c18-c22 unsaturated acids and their preparation,used for treating conditions of the heart and cardiovascular system
EP0285675A1 (de) Synthetische DNA-Kassetten mit Kodierung fuer artifizielle Proteine und deren Expression
ATE154389T1 (de) Verfahren zur herstellung von menschlichem ngf-2